Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas.
about
Dopamine and Somatostatin Analogues Resistance of Pituitary Tumors: Focus on Cytoskeleton InvolvementThe pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomasExpression of Stem Cell Markers and Dopamine D2 Receptors in Human and Rat Prolactinomas.Dopamine-induced apoptosis of lactotropes is mediated by the short isoform of D2 receptor.The human thioesterase II protein binds to a site on HIV-1 Nef critical for CD4 down-regulation.Genetically engineered mouse models of pituitary tumorsRoles of dopamine 2 receptor isoforms and g proteins in ethanol regulated prolactin synthesis and lactotropic cell proliferation.Angiogenesis in pituitary adenomas: human studies and new mutant mouse models.Dopamine receptor agonists for treating prolactinomas.Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas.Oncogenesis and mutagenesis of pituitary tumors.Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromeSecondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review.Long-Term Clinical Outcomes of Invasive Giant Prolactinomas after a Mean Ten-Year Followup.Pharmacogenetics of D2 dopamine receptor gene in prolactin-secreting pituitary adenomas.Resistant prolactinomas.Giant prolactinomas: the therapeutic approach.Current treatment options for hyperprolactinemia.Management of medically refractory prolactinoma.Cabergoline and prolactinomas: lack of association between DRD2 polymorphisms and response to treatment.Differential effects of nerve growth factor on expression of dopamine 2 receptor subtypes in GH3 rat pituitary tumor cells.Effect of 9-cis retinoic acid on dopamine D2 receptor expression in pituitary adenoma cells.Dopamine D2 receptor gene polymorphisms and response to cabergoline therapy in patients with prolactin-secreting pituitary adenomas.[Dopamine-agonist resistant prolactinomas: diagnosis and management].Cabergoline.Dopamine agonist resistance-related endocan promotes angiogenesis and cells viability of prolactinomas.Expression of dopamine 2 receptor subtype mRNA in clinically nonfunctioning pituitary adenomas.
P2860
Q26770701-02C98F7F-2059-42F1-BDA6-C7D492BCA4E6Q26772167-A44D14E9-D5A0-4620-A5E3-82D4CA742B3EQ33596189-59E46D11-799A-48B9-A5EC-3DE78150CC3FQ33862807-4D5DF8C6-57C7-4607-9BC4-053EA1D11B86Q33901672-D4AB02E1-7A1A-40DE-A088-8FFAE53FB183Q33984418-50A13A43-943F-454A-8D6B-DCCB111C5BD0Q34429544-1E98E4B1-9AAD-47BD-86B1-DEF82714985BQ34611189-2AF5DC54-F36A-45E1-80ED-846C3CC1F6E2Q34660851-7832A8BE-DE58-452F-A07A-10BD24BD92F3Q35530288-87AB74D6-1C4F-4A38-ABF7-6EB7BF914734Q36605354-22D34574-7FD0-43F7-9850-21AF7277C58FQ37314246-F0783EF8-D6D8-4000-A5F3-3B0B40986632Q37384810-F76FA612-8192-4DEF-AE8C-32E77E129B5BQ37480022-21D550E2-A512-4832-81CF-D9226C481FE3Q37636030-E318210A-C601-4DE2-A96A-12F794FD2909Q37853323-BBBF0E46-CCC8-428C-9A34-AB88C89F5D89Q38105620-D812ECDC-9906-4985-B63B-8A3ABD1DDCE8Q38112205-0FEE09C6-8FB9-435D-B60F-2FBFA0B052C6Q38154516-3EAC8B38-B130-4682-BA5F-F851FFA78EB4Q39184902-6D0EC0B6-6154-4286-8231-F8AB5022EF88Q39333836-65585B90-4FA1-4082-86DF-E0AD36A755D0Q39998318-5B5F87C5-9A6B-4F53-9F39-A40CF41BD83BQ46708438-70DFB7FD-ADDD-4EE6-8558-8869BCC3DBEEQ46917426-2FDE80AA-BDFC-4843-8789-D22B0A36A8E8Q48952149-1F7E07C2-70F3-4336-83CB-BF4758B13048Q53246001-4B22069D-6357-459F-B7EF-066C259ABE21Q54360050-773214EA-2C32-4533-8279-74F12F6D9985
P2860
Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年学术文章
@wuu
1994年学术文章
@zh-cn
1994年学术文章
@zh-hans
1994年学术文章
@zh-my
1994年学术文章
@zh-sg
1994年學術文章
@yue
1994年學術文章
@zh
1994年學術文章
@zh-hant
name
Decreased expression of the tw ...... ptine-resistant prolactinomas.
@en
Decreased expression of the tw ...... ptine-resistant prolactinomas.
@nl
type
label
Decreased expression of the tw ...... ptine-resistant prolactinomas.
@en
Decreased expression of the tw ...... ptine-resistant prolactinomas.
@nl
prefLabel
Decreased expression of the tw ...... ptine-resistant prolactinomas.
@en
Decreased expression of the tw ...... ptine-resistant prolactinomas.
@nl
P2093
P356
P1433
P1476
Decreased expression of the tw ...... iptine-resistant prolactinomas
@en
P2093
A Enjalbert
R Benarous
P304
P356
10.1159/000126764
P577
1994-09-01T00:00:00Z